Refinement of Operating Characteristics for Model‐Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology
Open Access
- 30 July 2026
- journal article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (8)
Abstract
The oncology market is evolving, with an increasing number of therapeutic options making the inference of treatment benefit from early development critical. The “Go” versus “No Go” decisions from such trials usually rely on probabilities of achieving meaningful improvements (effect sizes) in endpoints like objective response rate, tailored to products' profile, supporting faster transitions to confirmatory trials. Operating characteristics are sensitive to methodological details, important for establishing an early decision framework for ungating a pivotal clinical trial.Keywords
This publication has 3 references indexed in Scilit:
- Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition‐Survival Modeling FrameworkClinical Pharmacology & Therapeutics, 2023
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCNew England Journal of Medicine, 2018
- Modeling Survival Data: Extending the Cox Model2000